Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated strong financial performance, with a notable 57% year-over-year increase in revenue, driven by a higher mix of new prescriptions (NPS) within the pharmacy channel. The company has raised its 2025 and 2026 revenue estimates to $97.5 million and $136 million, respectively, alongside significant increases in quarterly forecasts due to robust demand and sales momentum. Additionally, management has updated their fiscal year 2025 guidance, reflecting confidence in maintaining a strong growth trajectory, with expectations of a 30-40% compound annual growth rate from 2024 to 2028.

Bears say

Beta Bionics Inc faces significant challenges that contribute to a negative outlook for its stock. Key issues include the potential failure to gain market share with its iLet Bionic Pancreas launch, increased competitive pressure, and delays in clinical development timelines that may hinder the company's ability to penetrate the pharmacy channel. Additionally, the lack of an FDA label for Type 2 diabetes adoption, coupled with the need for additional capital that could dilute shareholder value and unfavorable Medicare reimbursement proposals, exacerbates the company’s financial risks and could lead to downward pressure on revenue and profitability estimates.

BBNX has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 11 analysts, BBNX has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.